Ownership of the data from the EIND patients and only the EIND patients. If you consider that it’s only the data from the EIND patients and not future data, NP blocking the paper and ultimately delaying it (it had to be submitted to a different journal), the effort was not worth it. I don’t quite understand the long term implications of Incelldx owning the EIND data vs CYDY, but it’s my understanding that NP blocked the paper without informing Dr. BP that he was going to do so. CYDY owns leronlimab and Incelldx owns the laboratory tests, both of which make revenue.